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Abstract
The human microbiome is home to roughly 100 trillion microbial, which have
been shown to assist in various host physiological functions. Research shows that 
probiotic consumption may benefit host health. Therefore this is a two part study: project 
I is a study determining the effects of yogurt (probiotic) consumption on GI microbial 
structure and diversity, and project II is a study examining the effects of probiotic pill 
consumption has on stress response (cortisol) for healthy human test subjects exposed to 
a stressor.
In chapter II we used terminal restriction fragment length polymorphism, Sanger 
sequencing, and qPCR to characterize microbial communities of the GI tract. Non-metric 
multidimensional scaling analyses, Shannon Wiener diversity index values, and qPCR 
(targeting Lactobacillus) analysis showed a temporal influence on microbial community,
diversity and absolute abundance of Lactobacillus on human test subjects that consumed 
250g of yogurt per day for 42 consecutive days.
In chapter III, we quantitated Lactobacillus using qPCR and determined stress
response (via cortisol) using a salivary enzyme immune assay (EIA). Results from this 
study showed a decrease in stress response and an increase in the relative abundance of 
Lactobacillus in individuals that consumed one probiotic pill per day for 30 consecutive 
days. In comparison, the control group showed no changes in stress response or 
Lactobacillus.
Results from this study suggest the potential for probiotics as therapeutic 
treatment for host physiological function and stress response. However, further research 
is necessary to determine the effects probiotics have on human test subject.
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Prologue
This thesis is organized to produce initial drafts of 2 publications, i.e.,Chapter II and 
Chapter III will be submitted as 2 independent publications once research results are 
fully incorporated. Chapter I provides general background on the human gut 
microbiome. Chapter II is a study showing the effect long-term yogurt consumption has 
on GI microbial structure and diversity. Chapter III is a study examining the effects 
probiotic pill consumption has on stress response (cortisol) for healthy human test 
subjects that are exposed to stressor. Finally, chapter IV describes the future work for 
both studies.
Chapter I: Introduction
1.1 The human gut microbiome
In the past, research of microorganisms and human health has focused primarily 
on the negative impact pathogens have on the human body. Researchers have begun to 
investigate the microbial communities of human host and how they can have a beneficial 
effect on health. 
The term gut microbiome (also known as microbiota) is used to describe the 
ecological community of commensal and symbiotic microbes that reside in the 
gastrointestinal tract (GI) and all of their interacting genomes (Kinross et al., 2011). The 
human microbiome is estimated to be composed of nearly 100 trillion microbial cells that 
outnumber our human cells 10 to 1(Hamady & Knight, 2009; Turnbaugh et al., 2013). 
Many of the present microbiota have been shown to colonize virtually every surface of 
the human body that is exposed to the external environment, with the most heavily 
colonized organ being the GI tract (Sekirov, et al., 2010; Dominguez-Bello et al., 2010). 
The microbiota of the GI tract is not considered to be homogenous. Both cell density and 
microbial diversity increase as one moves further down the GI tract toward the colon,
 
 
2 
 
which contains roughly 1011-1012 bacteria cells per gram of luminal content (Ratsall, 
2004).
Although the human gut is home to nearly 50 bacterial phyla, it is dominated 
primarily by Bacteroidetes and Firmicutes, whereas Proteobacteria, Verrumicrobia, 
Acintobacteria, Fusobacteria, and Cyanobacteria are present in minute proportions 
(Sekirov, et al., 2010). Furthermore, some of the most dominant groups of bacteria of the 
human GI tract include Bifidobaceria, Lactobacillus, Strepococcous, and Clostridia
(Hamady et al, 2009).  It should be noted that limitations in fecal collection, DNA 
extraction, and molecular analysis can result in an underestimation of microbial 
groups/phyla. 
Development of the microbiome
The human microbiome is first inoculated immediately after passage through the 
birth canal (Koenig et al., 2011). Initially, the infant microbiome is moderately low in 
diversity. However, as the infant continues to progress in age, so does the abundance of
major bacterial taxonomic groups. Some of the earliest colonizers are typically aerobic 
organisms (e.g. Staphylococcus, Streptococcus, and Enterobacteria) whereas later 
organisms tend to be anaerobes (Eubacteria and Clostridia) (Palmer et al., 2007). Koenig 
and colleagues (2011) documented increased diversity over time in relation to a gradual 
change in community composition. Furthermore, Koenig showed that these gradual 
changes are in relation to the effect of typical life events of a growing infant (changes in 
diet or health, and use of antibiotics). After one year of life, the GI community, although 
distinct, has a convergence towards a microbial community similar to that of an adult 
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(García-Albiach et al., 2008). Many of the microbes that establish in the GI tract provide 
a range of beneficial functions for the human host, such as protection against pathogens, 
development of the immune system, as well as influencing basic physiological tasks such 
as digestion (Cho & Blaser 2012; DiBaise et al. 2008; Turnbaugh et al. 2013). 
Immunomodulation of GI tract
The immune system recognizes, responds to, and adapts to various pathogenic 
infections (Round & Mazmanian, 2009). Research utilizing Germ Free (GF) mice, which 
lack microbiota, have demonstrated the importance of gut microbiota on host immune 
health. For example, studies using GF mice have demonstrated a reduction in secreted 
immunoglobulin A and G, which are antibodies that protect the body from various 
infections. (Sekirov et al., 2010). 
Commensal micorbiota, such as Bifidobacterium and Lactobacillus (both are also 
probiotics, microorganisms consumed for their potential health benefits), have been 
shown to play an important role in host immunity. Bifidobacteria exhibit the ability to 
subdue the toxic effects of Shiga toxin (STX), which is produced by Enterohaemorrhagic 
Escherichia coli (EHEC) O157:H7 (Asahara et al., 2004 and Fukuda et al. 2011). Fukuda 
and colleagues (2011) showed that germ free (GF) mice that were fed E. coli O157:H7 
died within 7 days. However, if germ free mice were inoculated with Bifidobacterium 
longum subsp. longum JCM 1217, they survived. Furthermore, Fukuda showed that these 
effects could be attributed to increased production of acetate, which may promote the 
defense functions of epithelial cells, thus protecting the host against lethal infection. A 
similar study inoculating GF mice with a combination of Lactobacillus reuteri
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(commensal microbe of the GI tract) and EHEC showed that L. reuteri was able to 
suppress the colonization of EHEC and significantly  protect from the manifestation of 
disease, when compared to GF mice inoculated with only EHEC (Eaton et al., 2011).
Although, these microbes are a small representation of the vast ensemble of microbiota 
that inhabits the GI tract, they still demonstrate the importance the GI microbiota in 
assisting the host in immune defense. The inoculation with GF mice also suggests the 
possibility of alternative therapeutic approach for fighting various infections. 
Disruption of gut microbiota
Although the gut microbiome is fairly stable throughout our lives, various factors 
can have detrimental effects on the microbiome composition. Diet, age, and antibiotic 
usage can have both quantitative and qualitative effects on the microbiota (García-
Albiach et al., 2008).  For example, the use of antibiotics, which are commonly 
administered by clinical physicians, have been shown to reduce and alter bacterial 
population densities (Preidis & Versalovic, 2009).  This reduction in microbial 
communities has been shown to cause long-term disturbances for select individuals 
(Jernberg, et al., 2007). Antibiotics can reduce commensal microbiota that inhabit our GI 
tracts and allow for the overgrowth of opportunistic pathogens, such as Clostridium 
difficile. (Jernberg, et al., 2007; Bartlett et al., 2002). Chang and colleagues (2008) were
able to demonstrate by non-culturing techniques (i.e. molecular techniques), that 
recurrent C. difficile associated diarrhea (CDAD) was associated with lower microbial 
diversity when compared to control subjects (no signs of CDAD).
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Microbiota and Obesity
Recent studies provide evidence of obesity being associated with structural 
alterations in the GI microbiota and suggest the possibility for therapeutic manipulation 
of these microbes. One such study shows obesity to be associated with large-scale shifts 
in the dominant phyla of bacteria in both human and animal models (Ley 2010). The GI 
microbial communities of adult human monozygotic and dizygotic twins were evaluated 
to determine what correlations exist with obesity or leanness in terms of microbial 
community composition. The results showed that a diverse microbial community could 
yield a core microbiome at a functional level (e.g. a community of microbes that together 
have particular pathways of carbohydrate metabolism), while deviations from this core 
can be associated with different physiological states such as obesity (Turnbaugh et al., 
2008). Furthermore, microbial community gene content, as displayed in murine models, 
showed that an obese associated microbiome is enriched with genes that are capable of 
importing and metabolizing otherwise indigestible polysaccharides, which are then stored 
as adipose tissue. (Turnbaugh et al., 2012). Kadooka et al. (2010) were able to 
demonstrate the ability of the probiotic bacteria Lactobacillus gasserii to reduce adiposity 
and body weight in human test subjects, demonstrating potential benefits on metabolic 
disorders associated with obesity.
Probiotics
Previous research suggests that the microbiome is malleable and changes in the 
microbiome have consequences for human health. However, many therapeutic 
approaches targeting the microbiome may help counteract these negative effects. One 
 
 
6 
 
such positive manipulation is the use of probiotics, which are defined as “live 
microorganisms that when administered in adequate amounts confer a health benefit on 
the host” (Uyeno, et al., 2008). Over the past decade, probiotics have generated a vast 
interest as a potential new method of prevention for multiple gastrointestinal diseases, as
well as having an effect on the immunological response (Preidis & Versalovic, 2009). 
Sonnenburg and colleagues (2006) colonized germ-free rodents with Bacteroides 
thetaiotaomicron (a common commensal gut microbe) and Bifidobacterium longum (a 
common probiotic bacterium). Simultaneous whole genome transcriptional profiling of 
both species as well as analysis of the GI-associated carbohydrates revealed that the 
presence of B. longum stimulated an increase in polysaccharide degradation, thus 
demonstrating the effect probiotic bacteria can have on metabolic function (Sonnenburg, 
et al., 2006). Gao et al. (2010) showed the effect of probiotic dosage on antibiotic 
associated diarrhea (AAD) and CDAD after patients were administered antibiotics. 
Individuals who received probiotics, more specifically at higher doses, were less likely to 
have CDAD infection (Gao et al. 2010).
Yogurt
Although, in the past decade there is increased attention on viewing ourselves as 
microbial ecosystems and the knowledgeable benefits of probiotics, there is still not 
enough information about the dynamics of microbial communities on individuals who 
consume yogurt regularly (Maukonen et al 2008). One study compared the effects of 
lactobacilli-containing yogurt and non-probiotic containing yogurt on the composition of 
gut microbiota of healthy individuals who ingested a daily serving for 20 days. Utilizing 
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sequence-specific small subunit (SSU) rRNA cleavage method, with probes specific for 
the detection of common gut microbiota, they were able to determine that there was 
indeed a change in microbiota resulting from digestion of yogurt, primarily in two groups
of bacteria (Bacteroides and Prevotella., and the C.coccoides-E. rectalei group). 
However, the change did not seem to depend upon whether there were probiotic bacteria 
present (Uyeno et al., 2008).  Another study compared the effect of the antibiotic 
clindamycin on intestinal microflora in subjects ingesting yogurt with probiotic 
microorganisms (Lactobacillus acidophilus, Bifidbacterium lactis, and Lactobacillus 
F19) compared to subjects ingesting placebo yogurt. Based on culture techniques they 
were only able to conclude there to be no effect on Bacteroides fragilis of the GI tract 
(Sullivan et al., 2003). However, it should be noted that these studies never used broad 
molecular techniques, which allows for the analysis of unculturable microorganisms.
Chapter 2: A Dietary Effect of Yogurt Consumption on GI Microbial Communities
and Microbial Community Diversity of Healthy Individuals
Introduction
Although there is increased attention on the benefits that probiotic therapy may 
have on metabolic function and infections, there is still sparse information on the 
dynamics of microbial communities of individuals who consume commercially available 
multi-species probiotics. The aims of this study were to determine microbial community 
structure after a specific dosage of yogurt was administered to healthy human subjects.
Terminal restriction fragment length polymorphism (T-RFLP) (Liu et al., 1997) was used 
in this study to determine microbial community composition. T-RFLPs was chosen 
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because it is a one of the most commonly used high-throughput fingerprinting methods 
that is relatively affordable (Schüte et al., 2008). We hypothesized that introducing a 
yogurt diet to human test subjects will: i) increase the abundance of probiotic bacteria, ii)
alter the microbial community structure, and iii) increase GI microbial diversity.
Methods
Enumeration and confirmation of Probiotic Bacteria
Several commercially available brands of yogurt were selected from a local 
grocery store for this study. To test for their viability, 1g of each yogurt was added to 99
mL of sterile water (10-2) and a ten-fold serial dilution was carried out to 10-8.  A total of 
100 μl of the dilutions, ranging from 10-6-10-8, were used to inoculate agarose plates that 
enrich for Lactobacillus (LBS Agar) and Bifidobacterium (BSM Agar). For a control, a 
ten-fold serial dilution was performed on 1 mL of sterilized water. A total of 100 μl of 
diluted controls, ranging from 10-6-10-8, was used to inoculate LBS and BSM agarose 
plates. Inoculated plates were incubated anaerobically using GazPak Pouch System (BD 
technologies, Franklin Lakes, NJ USA) at 37°C for 48-72 hours. After bacterial growth 
was observed, colonies were enumerated and colony forming units (CFUs) calculated. 
Yogurt samples with the best CFU counts were then selected for the study in trial 1 and 2 
as described below.
Trial 1
Three healthy health test subjects ove4r the age of 18 were selected for this study. 
All participants had no known lactose intolerance and had consumed some form of 
 
 
9 
 
probiotics in the past (i.e. yogurt, probiotic pills, etc.). Subjects were labeled 
alphabetically (A, B, and C) for the purpose of anonymity.  To create a baseline (Day 0), 
test subjects were required to abstain from the consuming any form of probiotics or 
antibiotics while maintaining their regular diet for two weeks. After creating the baseline, 
individuals were then required to consume 450g of yogurt per day for 10 consecutive 
days while maintaining their regular eating habits. All volunteers gave written informed 
consent that was approved by the Institutional Review Board (IRB) at Youngstown State 
University.
Sample collection
Fresh fecal samples were collected on Day 0, Day 5 and Day 10 of the study. 
Each individual collected their own fecal samples in a sterile 90 mL container (Therapak 
Co., Buford, Georgia USA), which was sealed, placed on ice, and immediately delivered 
to the lab to be stored at -20°C until further analysis. 
Extraction of Fecal Microbial DNA
Microbial DNA was isolated from 180-220 mg of feces using the Powersoil DNA 
Isolation Kit (Mobio, Carlsbad, CA USA) following manufactures instructions with 
minor modifications.  Purified DNA was then stored at - 20°C until further analysis.
Terminal Restriction Fragment Length Polymorphism (T-RFLP)
A polymerase chain reaction was used to amplify 16s rRNA genes using primers 
8F (5’- AGAGTTTGATCATGGCTCAG-3’) and 1492R (5’-
 
 
10 
 
GGCTACCTTGCCACGACTTC-3’) (Zhang et al., 2008). The 8F primer was 5’ labeled 
with 6-carboxy-flourescein phosphoramidite (FAM).  Each 25 μl PCR reaction 
contained: 0.5 μl of each primer (10mM), 12. 5 μl Go Taq Green Master Mix 1X 
(Promega, Madison, WI USA), 2 μl of DNA, and 9.5 μl of molecular grade water. The 
IROORZLQJFRQGLWLRQVZHUHXVHGIRU3&5DPSOLILFDWLRQDQLQLWLDOGHQDWXULQJVWHSRIÛ&
for 3 minutes, 30 F\FOHVRIGHQDWXULQJDWÛ&IRUVHFRQGVDQQHDOLQJIRUÛ&IRU
VHFRQGVDQGHORQJDWLRQIRUÛ&IRUVHFRQGVIROORZHGE\DQHORQJDWLRQVWHSRIÛ&
for 7 minutes. PCR products were visualized by gel electrophoresis to verify proper 
amplification size and length of the amplified fragment. PCR products were then digested 
using HaeIII and incubating at 37°C for 16 hours. After digestion, samples were then 
purified using Wizard® SV Gel and PCR Clean-Up system (Promega, Madison, WI 
USA) according to manufactures instructions. 
Digested samples were then sent to the Ohio State University Plant Microbe and 
Genomics Facility (Columbus, OH USA) for fragment analysis using a 3730 DNA 
Analyzer (Applied Biosystems, Inc. Waltham, MA USA) using a LIZ1200 size standard 
and minimum peak height of 50 fluorescence units.  
Trial 2 
Six healthy test subjects over the age of 18 were selected for this study. All 
participants who consumed yogurt were had no prior history of lactose intolerance and 
must have consumed some form of probiotics in the past. Test subjects were assigned 
letters A, B, C, D, F, and G to keep anonymity. Test subject D was chosen a control 
subject since that individual had not consumed yogurt for several years, and did not 
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consume yogurt throughout the entire study. To create a baseline (Day 0), test subjects 
refrained from consuming any form of probiotics or antibiotics for one week. After a 
baseline was established, individuals consumed 250g of commercially available yogurt 
per day for 42 consecutive days. Each participant was to provide fecal samples on Day 0, 
7, 14, 21, 28, 35, and 42.  All volunteers gave written informed consent that was 
approved by the Institutional Review Board (IRB) at Youngstown State University. 
DNA Extraction
Microbial DNA was extracted from 180-220 mg of fecal material according 
QIAmp DNA Stool Isolation Kit (Qiagen, Valencia, CA, USA) protocol.  Purified DNA 
was then stored at - 20°C until further analysis. T-RFLP analysis was then performed on 
all microbial DNA that was isolated as described above.
DNA Preparation for Sanger Sequencing
Due to budget constraints, isolated microbial DNA from test subjects B, C, and D 
at Days 0 and 42 were selected for further molecular. Subjects B and C were chosen since 
they showed a change in microbial community composition from yogurt consumption 
based on T-RFLP data, and test subject D was chosen because they were the control.  
Microbial DNA isolated from fecal samples B, C and D for each sampling day 
(Day 0 and 42) was used to amplify bacterial 16s rRNA genes. Lactobacillus DNA was 
amplified using primers Lac1 (5’-AGCAGTAGGGAATCTTCCA-3’) and Lac2 (5’-
ATTYCACCGCTACACATG-3’) (Walter et al., 2001). Bifidobacterium was amplified 
using primers G-Bifid-F (5’-CTCCTGGAAACGGGTGG-3’) and G-Bifid-R (5’-
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CGTGTTCTTCCCGATATCTACA-3’) (Matsuki et al., 2004). Each PCR reaction 
(Bifidobacteria and LactobacillusFRQWDLQHGȝ0RIHDFKSULPHUȝORI*R7DT
0DVWHU0L[[ȝORI'1$DQGȝOof molecular grade water. Samples were 
amplified using Px2 Thermocycler (Thermoscientific, Waltham, MA, USA), the 
thermocycler settings for PCR amplification of Lactobacillus and Bifidobacteria can be 
found in Table 1. PCR products were then purified using Wizard® SV and PCR Clean-
Up System (Promega, Madison, WI, USA) according to manufacturer’s protocol. Clean 
samples were then frozen at -20 °C until further analysis. 
Clone Library
Cleaned PCR products were cloned into competent Ecsehrica coli cells using the 
Strataclone PCR cloning Kit (Agilent Technologies, Santa Clara, CA, USA) according to 
manufacturer’s protocol. Two sets of dilutions, pUC18 control plasmids (provided by 
kit), and provided StrataClone SoloPack competent controls were plated on LB medium, 
FRQWDLQLQJPJPORIDPSLFLOOLQDQGȝORI;-gal. Plated samples were then incubated 
over night at 37°C. White recombinants were then transferred to a 96-well plate 
containing LB medium, 0.1 mg/ml of ampicillin, and 10 % glycerol. Transferred samples 
were then incubated at 37°C overnight while shaken at 300 rpm. The insert size of the 
colony was then determined by PCR amplification as described for Lactobacillus and 
Bifidobacteria. We were able to isolate a total of 520 clones (273 from Lactobacillus and 
243 for Bifidobacteria), which were sequenced at the University of Kentucky Advanced 
Genetic Technologies Center, Lexington, Kentucky.
13 
Table 2-1 Thermocycler settings and bp length for primers used in this study.
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Phylogenetic Analyses of GI Microbial Communities
Bifidobacterium and Lactobacillus 16s rRNA gene sequences were first checked 
for quality using Vector NTI Software (Life Technologies Corp., NY, USA) and 
manually selected and organized. Sequences were aligned using Clustal W and 
evolutionary distance was constructed by neighbor-joining method (Saitou and Nei, 
1987). A phylogenetic tree was constructed using MEGA (Molecular Evolutionary 
Genetics Analysis; http://www.megasoftware.net/index.html) software, version 5.0 
(Kumar et al., 2004). Bootstrap resampling analysis of 100 replicates was performed 
when constructing the phylogenetic tree to estimate the confidence of tree topology.
Quantitative PCR analysis of Lactobacillus 16s rRNA genes
To quantify Lactobacillus genes, quantitative PCR (qPCR) was performed using 
primers Lac1 and Lac2. Standard curves were constructed from isolated Lactobacillus
DNA from probiotic pills grown on selective media (LBS). Standards constructed by 
performing a serial dilution of 10-3- 10-9 of Lactobacillus DNA.  
Real-time PCR was performed using the iQ™5 real-time detection system (Bio-
Rad Inc., Hercules, CA, USA). The qPCR reaction was performed using a total volume 
RIȝORIWKHIROORZLQJUHDJHQWVȝO of SYBR Green buffer (Qiagen, Valencia, CA, 
USA), 9.0 ȝO RI51DVHIUHHZDWHUȝ0RISULPHUDQG ȝO of DNA. The reaction 
FRQGLWLRQVIRUDPSOLILFDWLRQZHUHÛ&IRUPLQF\FOHVRIÛ&IRUVDQGÛ&IRU
30s.
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Statistical Analysis
Nonmetric multidimensional scaling (NMDS) was used to compare T-RFLP 
fragments of gut microbial DNA from different subjects at various time points. NMDS 
was chosen because it is an ordination technique that doesn’t require linear variables (as 
in principles-component analysis). There is also no need for specific distance measures 
(covariance), and it makes few assumptions about the data (Holland, 2008). Statistical 
analysis performed using SPSS 12.0 for windows.
The Shannon Wiener diversity index was calculated using restriction fragments 
(T-RFs) to analyze the microbial diversity for each test subject at Days 0, 7, 14, 21, 28, 
35, and 42. 
Results
Terminal Restriction Fragment Length Polymorphism (T-RFLP) analysis for GI 
microbiome variation and diversity
A total of 61 bacterial terminal restriction fragments (T-RFs), ranging from 59 to 
438 bp in length, were detected from collected fecal samples (Table 2-2, Fig. 2-1).  On 
average, 25 T-RFs were recovered for test subject A, 32 T-RFs for test subject B, 33 T-
RFs for test subject C, 28 T-RFs for test subject D, 26 T-RFs for test subject F, and 24 T-
RFs for test subject G (Table 2-2).
Analysis of T-RFLP profiles by nonmetric multidimensional scaling (NMDS) 
differentiated the GI microbial samples according to sampling time (Fig. 2-2). T-RFs at 
Day 0 were the furthest away from the center of the axis for test subjects A, B, and F, but 
they begin to differentiate at Day 7. By Day 14 of yogurt consumption, microbial 
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communities begin to cluster together, indicating microbial communities of similar 
composition (Fig. 2-2).  Test subject D (control) also differentiated over time, but not as 
drastically as the experimental group (Fig. 2-2). Test subject A begins to cluster toward 
the center of the axis, but at Day 42 it migrates away from the cluster (Fig. 2-2).
Shannon Wiener diversity index analysis (Fig. 3; Table 3) showed the highest 
index value (H’) for test subject C for all time points except for Day 28. Index values also 
showed an increase in microbial diversity from Day 0 to Day 14. However, after Day 14 
microbial diversity appears to plateau and stay in a state of flux throughout the remainder 
of the study (Fig. 3; Table 3). Although, it should be noted that all test subjects had 
higher index values at each time point, when compared to Day 0, except for test subjects 
A and D (control subject) (Fig. 3; Table 3). Test subjects G and F had the lowest index 
values at Day 0 in comparison to all other test subjects. Test subjects G and F also 
showed the greatest increased index values for all time points, when compared to Day 0
(Fig. 3; Table 3).
17 
Table 2-2 Number of T-RFs for human test subjects at Day 0 to Day 42 and average 
number of T-RFs for all human test subjects in this study.
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Fig. 2-1 GI bacterial community composition from test subjects A, B, C, F, G, and D 
(control) at times 0, 7, 14, 21, 28, 35, and 42. The figures show relative abundance 
of terminal restriction fragments (T-RFs) that contribute to the community with 
more than 2 %.  
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Fig. 2-2 NMDS ordination showing similarity and distribution of microbial 
communities (T-RFs of the 16s rRNA gene) for test subjects A, B, C, D, and F at 
times 0,7,14, and 42.  Each color represents the microbial community from and 
individual test subject. Circles = Experimental Group; Triangles = Control. 
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Table 2-3 Diversity indexes based on the number of terminal restriction fragments (T-
RFs) recovered form test subjects A, B, C, D, F, and G at Days 0, 7, 14, 21, 28, and 45. 
Bold values indicates highest index values at each time point.
Day A B C D F G
0 2.49 2.63 3.06 2.77 2.25 2.32
7 2.72 2.86 3.18 2.98 2.44 2.36
14 2.78 3.11 3.33 3.07 3.18 2.39
21 2.64 3.00 3.02 2.80 2.35 2.86
28 2.84 3.38 3.32 2.83 2.87 2.71
35 2.56 2.91 3.00 2.48 2.83 2.60
42 2.38 3.11 3.13 2.99 2.73 2.67
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Fig. 2-3 Shannon diversity index (H’) values showing variances in diversity for 
test subjects A, B, C, F, G, and D (control) at Days 0, 7, 14, 21, 28, 35, and 42. 
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Bacterial Taxa
Sequences from a 282 Bifidobacteria and 272 Lactobacillus bacterial clones were 
analyzed for quality using Vector NTI Software (Life Technologies Corp., NY, USA) for 
test subjects B, C and D (control) at Days 0 and 42. A total of 263 Bifidiobacterium (67 
for B, 120 for C, and 76 for D) gene sequences and 146 Lactobacillus (48 for B, 39 for C, 
and 59 for D) gene sequences were analyzed. Recovered sequences were matched to 
sequences found using BLASTn with the highest score values. 
Clone libraries constructed of Bifidobacterium at the species level for sample B0
was composed of Bifidobacterium longum (19%) and Bifidobacterium pseudocaenulatum 
(81%) and sample B6 was composed primarily of B.longum. Sample C0 consisted of B. 
longum (21%), Bifidobacterium bifidum (44%), Bifidobacterium adolscentis (24%), and 
B. pseudocatenalatum (10%) and sample C6 contained Alloscardovia omnicolens (4%), 
B. longum (16%), B. bifidum (12%) and B. adolescentis (58%).  Sample D0 was made up 
of B. longum (47%), B. adolescentis (44%) and B. pseudocatenulatum (9%) while sample 
D6 consisted of B. bifidum (18%), B. adolescentis (36%), and B.pseudocatenulatum 
(45%). 
Clone libraries constructed from PCR products using species specific primers for
Lactobacillus for sample B0 was composed Lactobacillus iners (27%) and Lactobacillus 
casei (73%). Sample B6 consisted of L. casei (78%) and Lactobacillus rhamnosus (18%). 
Sample C0 consisted of Lactobacillus gassrei (45%), Lactobacillus crispatus (20%), 
L.casei (10%), Lactobacillus ruminis (5%), and Pediococcus stilesii (20%).  Sample C6 
contained L. casei (32%), L. rhamnosus (32%), L. ruminis (26%) and Lactobacillus 
reutrei (11%). Sample D0 contained L. gasseri (8%) , L. cripatus (4%), Lactobacillus 
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sakei (4%), L. casei (16%), L. rhamnosus (28%), Dolosigranulum pigrum (4%), 
Granulicatella adiacens (4%), L. reuteri (4%), Pedicoccus stilesii (24%), and 
Lactobacillus plantarum (8%). Sample D6 contained L. gasseri (58%), Lactobacillus 
elbruckeii subsp. Bulgaricus (9%) Lactobacillus reuteri (21%), Weisella 
paramesenteroides (3%), Lactobacillus homohiochii (6%).
Quantitative PCR of Lactobacillus 16s rRNA genes
Absolute quantification of Lactobacillus 16s rRNA by qPCR (Fig. 2-6) revealed 
that test subject B at Day 0 had 6.87e-ȝ0 Lactobacillus, which increased to 7.82e-01
ȝ0 at Day 42, indicating an increase in Lactobacillus bacteria. Interestingly, test subject 
C showed a slight decrease in Lactobacillus 16s rRNA gene content from Day 0 (2.33e-
01 ȝ0WR'D\H-02 ȝ0&RQWUROVXEMHFW'DW'D\KDGH-04 ȝ0RI
Lactobacillus genes and at Day 6 2.42e-ȝ0
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Fig. 2-4 Phylogenetic tree of Bifidobacterium 16s rRNA gene sequences retrieved 
from test subjects B, C, and D (control) fecal material. The tree was constructed 
using the neighbor-joining method. Bootsrap values (in %) are based on 100 
replicates each (distance and minimal evolution) and are shown at nodes with 
>50% support.  
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Fig. 2-5 Phylogenetic tree of Lactobacillus 16s rRNA gene sequences 
retrieved from test subjects B, C, and D (control) fecal material. The tree 
was constructed using the neighbor-joining method. Bootsrap values (in 
%) are based on 100 replicates each (distance and minimal evolution) and 
are shown at nodes with >50% support.  
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Figure 2-6: Quantitative PCR for Lactobacillus detected from human subjects B, C, and 
D at Days 0 and 42. Standard curve (blue diamonds) was  from Lactobacillus DNA.
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Discussion
In this study, we examined the temporal changes of GI microbial community 
composition and diversity of healthy human test subjects that consumed 250g of yogurt 
per day for 42 consecutive days. Samples were analyzed by terminal restriction fragment 
length polymorphism (T-RFLP) as a culture independent technique that allows for the 
analysis of microbial communities by generating a fingerprint of the dominant microbial 
groups (Karlsson et al. 2009). Although, culture-dependent methods have provided 
information about intestinal microbiota, only about 20% are actually cultivable (Eckburg 
et al. 2005). Molecular techniques have now become the standard for analyzing the 
human microbiome (Heilig et al., 2002)
With T-RFLP analysis, the change in microbial community composition was 
analyzed statistically by non-metric multidimensional scaling (NMDS). Results from 
NMDS show a trend in which the microbial community composition begins to change
after 7 days of yogurt consumption. By days 14 and 42, the microbial communities begin 
to cluster together for individuals consuming yogurt. This clustering suggests that the 
microbial communities are becoming structurally more similar after 14 days of yogurt 
consumption and maintain that similarity for the remainder of the study. Previous 
research by David et al. (2014) has shown similar short-term alterations of the gut 
microbiome when a diet is changed between an animal or plant based diet. Furthermore, 
clustering of GI microbial communities may be the result of the test subjects sharing 
similar dietary habits, in terms of yogurt consumption. One study analyzing the gut 
microbiome of individuals fed the same diet showed no clustering of microbial 
communities, but did see inter-subject variation (Wang et al. 2006). However, it should 
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be noted that the study by Wang and coworkers only lasted for 10 days, where our study 
lasted 42 days, allowing for a better representation of the long-term effects an altered-diet 
might have.
The Shannon-Wiener index, a commonly used estimate of diversity, was used to 
quantify changes in diversity after the consumption of yogurt (Spellerberg and Fedor, 
2003). The Shannon index takes into account both the number of bacterial groups 
(richness) and the abundance (evenness) of each. The Shannon index also takes into 
account of changes in rare groups that maybe present within an ecosystem (Karlsson et 
al. 2010).
Shannon index values based on terminal restriction fragments (T-RFs), showed an 
increase in microbial diversity for all test subjects that participated in this study. 
Interestingly, after two weeks of yogurt consumption, the GI diversity appears to be in a 
state of flux through the duration of the study. This flux could be a result of bacterial
species competition with the introduction of probiotic bacteria. Furthermore, individuals 
with the lowest Day 0 microbial index values (Subjects F and G), had the highest increase 
in microbial diversity. In comparison, test subject C, which had the highest microbial 
diversity, did not see as drastic an increase in diversity. Because of individuals G and F 
having lower diversity it may have provided an opportunity for other microorganism to 
establish in the GI tract.
Due to budget restraints, clone libraries of only test subjects B, C, and D (control) 
were sequenced via Sanger method at Days 0 and 42. Results from this study showed a 
decreased number of cloned sequences for B. pseudocatenulatum and B. bifidum for test 
subjects consuming yogurt, while the control subject showed an increase in B. 
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pseudocatenulatum and B. bifidum. Lactobacillus showed no major trends for the 
experimental group and control in this study. This could be due to the low number of 
clones that were Sanger sequenced. Because of this lack of “deep sequencing” there is 
poor representation of the microbial communities present within the GI tract (Mardis, 
2008).
Conclusion
This is the first study to look at the long-scale effects of healthy human test 
subjects consuming yogurt daily. Many studies utilizing yogurt typically last 10-20 days 
and use either culturing techniques or identified certain microorganisms using probe 
markers (Sullivan et al., 2003; Uyeno et al., 2008). Microbial community composition, 
based on T-RFLP analysis, demonstrates temporal changes in diversity with the 
consumption of yogurt. Furthermore, individuals with lower microbial GI diversity 
appear to have the greatest increase in diversity when introduced to yogurt and maintain 
increased diversity throughout the study. Finally quantitative PCR (qPCR) analysis 
showed increase in absolute quantity of Lactobacillus for test subjects consuming yogurt 
daily. However, individuals with already diverse communities do not see as drastic a 
change in Lactobacillus gene content. Therefore, this study suggests that regular 
consumption of yogurt may increase microbial diversity in individuals who have 
relatively low diversity. Lower microbial diversity of the GI tract has been shown to be 
associated with recurring CDAD, obesity, and Crohn’s disease, as well as many other 
diseases (Cheng et al., 2008; Turnbaugh et al., 2009; Ott et al., 2004). Thus, probiotics 
such as yogurt may provide a therapeutic/preventive approach to these diseases.
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Chapter 3: The Effect of Probiotics on Healthy Human GI Microbial Community 
and Stress Response
Introduction
The fields of microbiology and neuroscience have for the most part developed as
separate entities.  However, it has recently been recognized that the microbiota within the 
gut influence multiple aspects of physiology, one such influence is via the gut-brain axis. 
The term gut-brain axis refers to the bi-directional signaling that exists between the 
central nervous system (CNS) and the GI tract (Chen et al. 2013, Grenham et al. 2011).  
Furthermore, it has been suggested that the endocrine (cortisol), immune (cytokines), and 
neural (vagus and enteric nervous system) pathways are potentially direct and indirect 
ways in which the gut microbiota can modulate the gut-brain axis (see fig. 2) (Cryan and 
Dinan, 2012).
Hypothalamic-Pituitary Adrenal (HPA) Axis (Fig. 3-1)
The hypothalamic-pituitary adrenal (HPA) axis is a major part of the 
neuroendocrine system that is responsible for the regulating stress response, digestion, 
immune response, as well as many other biological processes (Hans, 1974). In response 
to a stressor, (i.e. illness or fear) corticotrophin releasing hormone (CRH), also known as 
corticotrophin releasing factor (CRF), is released from the hypothalamus to the adrenal 
portion of the pituitary gland. The binding of CRH to receptors on the pituitary gland 
induces the release of adrenal corticotropic hormone (ACTH), which is then carried to the 
adrenal cortex via blood cells. The adrenal gland then releases the corticosteroid, cortisol,
into the body to respond to a stressor (Smith and Vale, 2006).
31 
Fig. 3-1 Pathways involved in the bi-directional signaling for the gut-brain axis.  
The hypothalamic-pituitary-adrenal axis is produces cortisol as a result of 
stress. Cortisol secretions can affect immune cells, such as cytokines; alter gut 
permeability and change GI microbial composition. GI microbes can also have 
an influence on brain function via the vagus nerve through tryptophan 
metabolism and short chain fatty acid (SCFA) production. GI microbiota can also 
alter immune system by regulating cytokine levels, which can also alter brain 
function. ACTH, adrenocorticotrophic hormone; CRH, corticotropin-releasing 
factor.  (Modified from Dinan and Cryan, 2013, Chen et al. 2013). 
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Microbiota and Stress
GF and specific pathogen free (SPF) mice have been the key models for 
demonstrating the effects microbiota can have on stress. One such study performed by 
Sudo et al. (2004) was able to show correlation between the HPA axis and gut microbiota 
using these GF and SPF mice. In this study, GF mice were shown to have an exaggerated 
corticosterone (CORT) and ACTH response during restraint testing in comparison to SPF 
mice. Furthermore, re-colonization of GF mice with fecal content of SPF mice was 
shown to partially reverse the stress response, while monocolonization with 
Bifidobacterium infantis fully reversed the exaggerated HPA response to the restraint 
stressor, if introduced at earlier developmental stages (Sudo, et al., 2004).  Results from 
these studies suggest that microbial communities within the GI tract, more specifically B. 
infantis, may regulate cortisol production. Further research is required to fully understand 
which microbes may influence stress response. 
A more recent study performed by Heijtz and colleagues (2011) also showed the 
importance of gut microbiota and their ability to modulate the gut-brain axis. In this study 
GF mice were shown to have increased motor activity and reduced anxiety-like behaviors 
in comparison to SPF mice. This behavioral phenotype was also shown to be in relation 
to an altered expression of genes associated with motor control and anxiety. Similar to 
Sudo et al. (2004) results, early recolonization of GF mice with fecal material from SPF 
mice resulted in GF mice displaying similar characteristics to SPF mice (Heijtz et al., 
2011).  These studies have provided evidence to the role gut microbiota play in the 
development of healthy CNS function as well as demonstrate their effect on stress and 
anxiety.
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Early Evidence for Psychotropic Benefits from Probiotics
Research on irritable bowel disease (IBD) has led to a link between GI disorders and 
stress. It has been shown that more than 50%-90% of patients who suffer from IBD also 
suffer from psychological disturbances during periods of intestinal distress (Messaoudi et 
al., 2010).  Additionally, research has shown that probiotics can alleviate some of the 
symptoms of GI disorders, which suggests that probiotics may also offer a novel 
therapeutic approach for the treatment of anxiety and decreasing stress responses (Bercik 
et al., 2005, Grenham et al., 2011). 
Preclinical research using rodent models has provided the interesting possibility 
of using probiotics for the treatment of CNS disorders (Grenham et al. 2011, Cryan and 
Dinan, 2012). Work by Gareau and colleagues (2007) has shown that administration of 
probioitc Lactobacillus to neonate maternally separated (MS) rats reduced corticosterone 
levels after 20 days in comparison to neonate MS rats receiving a saline solution. A 
recent study analyzing the effects of Lactobacillus rhamnosus (JB-1) showed a decreased 
anxiety-like behavior and reduced levels of corticosterone levels in “normal”, healthy 
mice (Bravo et al., 2011). 
To date, there a very few studies that have analyzed the effects probiotics might 
have on human test subjects. One study using a combination of Lactobacillus helveticus 
R0052 and Bifidobaterium longum R0175 examined their effects on mental health as well
as cortisol levels. This probiotic cocktail had beneficial psychological effects and reduced 
cortisol levels (Messaoudi et al., 2011). 
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Although, these studies provide early evidence of probiotics as a therapeutic 
approach to alleviating psychological and physical stress, there is still not enough 
information on their effects on human subjects. We will also investigate the effects of this 
multi-species probiotic on GI microbial community composition. Therefore, this study 
looks to evaluate the possible beneficial effects probiotics may provide to healthy human 
test subjects and induced stress through analysis of salivary cortisol.  We will also asses
the effects multi-species probiotics might have on an individual’s perceived stress using a 
Perceived Stress Questionnaire (PSQ). Based on previous research, I hypothesize 
introducing probiotics will: 1) increase the abundance of probiotic species in the human 
GI tract, 2) increase the microbial diversity within the human GI tract, and 3) positively 
affect stress levels in human test subjects exposed to a stressor. 
Methods
Subjects
Fifteen healthy individuals over the age of 18 were included in the study. 
Individuals who had irregular production of cortisol or were taking any medication that 
may suppress adrenal function (i.e. anxiety medication or anti-inflammatories) were 
excluded from this study. Each test subject was provided with a 30-day supply of 
commercially available probiotic pills containing Lactobacillus (acidophilus and 
rhamnosus) and Bifidobacterium (lactics, longum, breve, and bifidum). All participants 
were asked to follow their normal diets throughout the entire study. Participants were 
asked to keep a daily dietary journal. Test subjects were to also report daily exercise,
rating the intensity on a scale of 1-4 (1 being of lower intensity and 4 being of higher 
intensity).  Finally, all test subjects were asked to report anytime they felt ill, were 
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constipated, had diarrhea, or consumed any other form of probiotics or antibiotics. All 
volunteers gave written informed consent that was approved by the Institutional Review
Board (IRB) at Youngstown State University. 
Study Design
The total duration of the study, including probiotic pill consumption and follow-
up period, was 60 days. Each test subject was required to consume one probiotic pill (~1 
billion CFUs per pill) per day for 30 consecutive days.  After the 30-day probiotic pill 
regiment, test subjects refrained from consuming the supplied probiotic pills, but still 
followed their regular eating habits for 30 additional days.  
To induce stress, test subjects were to perform the Elevated High Ropes Course 
(EHRC) (Fig. 3-2) every two weeks. The high ropes course consisted of various obstacles 
located 6.09 meters above the ground level. Each test subject was to perform this task to 
the best of their ability. 
36 
Fig. 3-2 Elevated high ropes course (EHRC) to induce stress on human test subject. 
The course is 4.6 meters up a gymnasium floor. The EHRC is located at 
Youngstown State University’s Recreational Center, Youngstown OH, USA.
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Sample Collection
Fresh fecal samples were collected on Day 0 of the probiotic study and every 2 
weeks after that until day 30 of the probiotic pill consumption was reached (3 fecal 
collections; Day 0, Day 15, and Day 30).   A final follow-up fecal sample was then 
collected 30 days after individuals stopped their probiotic regiment (Day 60). Each 
individual collected his or her own fecal samples in a sterile 90 mL container (Therapak 
Co., Buford, Georgia USA) and delivered to the laboratory within 12 hours of defecation. 
Test subjects also collected their own saliva samples in the morning when they first 
awoke, once before performing EHRC, and once 20 minutes after completing EHRC. 
Saliva was collected from test subjects using the Salimetrics® Oral Swab (SOS) 
(Salimetrics, State College, PA USA). 
Perceived Stress and Bowel Health Questionnaires 
On the same day as fecal collection, a perceived stress questionnaire (PSQ) 
(Levinstein et al., 1993) was administered consisting of 31 items. The PSQ is an 
instrument for assessing stressful life events and the circumstances that can trigger 
disease like symptoms that may alter one psychological state. The questionnaire consisted 
of 30 questions pertaining to stressful feelings and experiences that individuals may feel 
during a two-week period and one question pertaining to stressful feelings they 
experience during the Elevated high ropes course (EHRC). Each test subject was to 
indicate on a scale from 1 (almost never) to 4 (usually) how frequently they experienced 
a certain stress-related feeling. Higher scores indicate greater levels of stress. 
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A Bowel Health Questionnaire was also administered consisting of 11 items. This 
questionnaire was given to determine the effects probiotic pills might have on various 
gastrointestinal functions in relation health (i.e. bowel movement, flatulence, etc.) For 
seven of the questions each test subject was to indicate on a scale from 1 (almost never) 
to 4 (usually) how frequently they experienced a certain bowel related issues. Higher 
scores indicate poorer health.  Another four question were then asked individuals to 
record how many times they were constipated, had diarrhea, passed a stool, or have taken 
a stool softener. 
DNA Extraction of Fecal Microbial DNA
Microbial DNA was isolated from 200-300 mg of feces using a modified bead 
beating method (Yu and Morrison, 2004) to minimize DNA shearing for downstream 
applications. Extracted DNA was then purified using QIAamp DNA Stool Mini Kit 
(Qiagen, Valencia, Ca USA) and quantified using a NanoDrop (Thermoscientific, 
Waltham, MA USA). Extracted microbial DNA was then normalized to 10 ng/μl, 
aliquoted, and stored at -20°C until further analysis.
Microbial DNA Amplification
16s rRNA genes of normalized microbial DNA (gDNA) were amplified using 
universal bacteria, Lactobacillus and Bifidobacterium primers (Table 2). Each 20 μl PCR 
reaction contained: 0.04 μl of each primer (0.2u μM), 10 μl GoTaq Green Master Mix 1x 
(Promega, Madison, WI USA), 1 μl of genomic DNA (10ng/μl), and 8.2 μl of molecular 
grade water. PCR reactions were amplified using Px2 Thermocycler (Thermoscientific, 
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Waltham, MA USA) and gel electrophoresis was run to verify successful amplification of 
PCR products.  PCR samples of proper length were then pooled together and shipped to 
Case Western Reserve University Genomics Core in Cleveland Ohio to perform PCR 
clean up and Next Generation Sequencing using the MiSeq (Illumina, San Diego, CA 
USA). 
Enzyme Immunoassay of Saliva Samples
To measure salivary cortisol levels an enzyme immunoassay (EIA) was 
performed on collected saliva samples from test subjects.  To perform this task, a High 
Sensitive Salivary Enzyme Immunoassay Kit (Salimetrics, State College, PA USA) was 
used according to the manufactures instructions with minor modifications. The EIA 
samples were read at absorbance 450 nm using a photospectrometer.
Quantitative PCR for Lactobacillus 16s rRNA genes
To determine relative quantity of Lactobacillus genes, quantitative PCR (qPCR) 
was performed using primers Lac1 and Lac2. Standard curves were constructed from 
isolated Lactobacillus DNA from probiotic pills dissolved in autoclaved water and then 
grown on selective media (LBS). Standards were constructed by performing serial 
dilutions of 10-3- 10-9 of Lactobacillus DNA.  
Real-time PCR was performed using the iQ™5 real-time detection system (Bio-
Rad Inc., Hercules, CA, USA). The qPCR reaction was performed using a total volume 
RIȝORIWKHIROORZLQJUHDJHQWVȝO of SYBR Green buffer ((Qiagen, Valencia, 
CA, USA), 9.0 ȝO RI51DVHIUHHZDWHUȝ0RISULPHUDQG ng of DNA. The reaction 
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conditions fRUDPSOLILFDWLRQZHUHÛ&IRUPLQF\FOHVRIÛ&IRUVDQGÛ&IRU
30s. To determine specificity of amplification, a melt curve was performed after the last 
F\FOHZKLFKFRQVLVWHGRIF\FOHVE\VORZLQJKHDWLQJIURPÛ&WRÛ&
Statistical Analyses
To determine cortisol concentrations, a 4-parameter non-linear regression analysis 
was performed on collected EIA 450 nm absorbance readings. Statistical analysis 
performed using My Assays Inc., an online database tool (myassays.com).
A two-way repeated measures analysis of variance (ANVOA) was used to 
determine statistical significance of a probiotic regimen on stress response, Lactobacillus 
relative abundance, and sampling dates. Statistical analysis performed using SPSS 12.0 
for windows.
Results
Stress Response for treatment and control groups
Stress response data was collected by subtracting the after cortisol concentrations 
from the before cortisol concentrations. Calculated stress response was then averaged for 
each experimental group (control, treatment) at Day 0, 15, 30, and 60. (Table 3-1, Figure 
3-1). Two-way repeated measures ANOVA analysis of time of treatment revealed no 
statistical significance for this study (p = .585), but it should be noted that a trend was 
observed overtime.  
$YHUDJHVWUHVVUHVSRQVHIRUWKHWUHDWPHQWJURXSDW'D\ZDVȝg/dL, which 
ZDVPXFKKLJKHUWKDQWKHFRQWUROJURXSȝJG/$IWHUGD\VRISURELRWLFSLOO
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FRQVXPSWLRQVWUHVVUHVSRQVHGHFUHDVHGWRȝJG/ZKLFKZDVDORZHUVWUHVV
response than the control group (0.072 ȝJG/%\'D\WKHVWUHVVUHVSRQVHLQFUeased 
to 0.062, but day 30 stress response for the treatment group was still lower than Day 0 of 
the study. After stopping probiotic pill regimen, stress response remained relatively 
unchanged by Day 60 (0.066) of the study, but still remained lower than Day 0. The 
control group stress response remained relatively unchanged throughout the entire study, 
only increasing slightly at Day 60 (0.113).
Quantitative PCR (qPCR) for Lactobacillus 16s rRNA
Average relative abundance for Lactobacillus genes was determined for each 
experimental group in this study (Table 3-2). Two-way repeated measures ANOVA 
analysis of time and treatment revealed no statistical significance Lactobacillus relative 
abundance for this study (p = .478), but it should be noted that a trend was observed 
overtime.
Relative abundance for Lactobacillus 16s rRNA genes was 0.004 at Day 0. At 
Day 15 of the study a slight increase in relative abundance (0.024) observed and by Day 
30 of the study, there was a substantial increase of Lactobacillus relative abundance 
(0.389). Interestingly, after Day 30 of the study probiotic regimen was stopped, this 
resulted in a decrease in relative abundance to 0.064. 
The control group at Day 0 had the lowest relative abundance (0.002) in 
comparison to all other samples. At Day 15 relative abundance increased to 0.073 and 
0.027 at Day 30, but the increase in abundance wasn’t as drastic as seen in the treatment 
group. Relative abundance remained stable from Day 30 to Day 60 (0.019).
42 
Fig. 3-3 Average change in cortisol (ug/dl) response for control (green) and 
treatment (blue) over timespan of the study (time shown in days). Treatment was 
ended at day 30 to create a washout period. Stress Response = after EHC – before 
EHC.
Stop Probiotic 
R
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Fig. 3-4 Mean relative abundance of Lactobacillus 16s rRNA genes 
for experimental and control groups. Relative abundance determined 
by quantitative PCR. Probiotic regimen stopped at day 30 to create a 
washout period.
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Discussion
Many previous studies have used rodent models to analyze the effects microbial 
communities have on the stress response. However, this study is one of the first to 
analyze the effects probiotics have on healthy human subjects that are exposed to a 
stressor. For this study, the stress response was measured by salivary cortisol EIA. This 
method was selected because it is a proven and reliable method to the amount of unbound 
cortisol found in blood and allows for stress free analysis (Kirschbaum and Hellhammer, 
1994).  Molecular analysis via qPCR was also used in this study because it allows for 
measurement of change in select microbial genes that might be underrepresented in the 
microbial populations detected using culture techniques and Sanger sequencing. 
The calculated stress response from salivary cortisol, although statistically 
insignificant showed a trend. Individuals that consumed one probiotic pill per day 
resulted in a drastic decrease in stress response at Day 15 (Fig. 3-3). This decrease in 
stress response appeared to be maintained throughout the entire study even after the 
probiotic regimen was stopped. A study using mice found similar decreases in serum 
cortisol when the mice were fed the probiotic L. rhamnosus before being exposed to a 
stressor (Bravo et al., 2011). Additionally, vagotomized mice that were fed L. rhamnosus 
did not have the same cortisol reduction as mice with the vagal nerve still intact, 
suggesting the vagus nerve is the major modulatory communication link between gut 
microbiota and the gut brain axis (Bravo et al., 2011).
QPCR analysis, although statically insignificant, showed an increase in relative 
abundance for Lactobacillus 16s detected rRNA genes from day 0 to Day 15 and a drastic 
spike of Lactobacillus genes by Day 30 (Fig. 3-4). After stopping probiotic treatment on 
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Day 30, a decrease in relative abundance was seen. In comparison the control group saw 
a consistent relative abundance of Lactobacillus genes throughout the entire study. These 
results suggest that continued use of probiotic administration results in an increase in 
Lactobacillus over time (Fig. 3-4). However, this increase from probiotic administration 
is only temporary.
Conclusion
Although, both qPCR and stress response analysis were statically insignificant, a 
trend was seen in this study that suggests an increase in probiotic bacteria can lead to a
decreased stress response for human test subjects. The reason insignificant values were 
seen could be due to low numbers of test subjects in this study. Ideally, a total of 30 test 
subjects would have resulted in greater significance. Therefore, future studies should 
include more test subjects when analyzing the effects probiotics have on stress response.
Chapter IV: Summary, Future Work, and Recommendations
T-RFLP data from Chapter II demonstrated increases in microbial diversity for 
human test subjects that consumed yogurt for 14 days. Furthermore, test subjects with 
lower microbial communities saw a more drastic increase in microbial diversity, but test 
subjects with higher diversity did not see as much increase. After 14 days of yogurt 
consumption, there is a fluctuation in diversity, which would suggest introducing bacteria 
from yogurt results in competition for limited space and resources. NMDS analysis of T-
RFs showed that microbial communities within the GI tract are influenced by a yogurt 
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diet. NMDS also suggested that microbial communities of individual subjects become 
similar in composition over time.
Future work for this study includes analyzing microbial communities by Next 
Generation Sequencing using primers specific for Bifidobacteria, Lactobacillus, and 
universal bacteria. NGS will be used because it provides more reads (96 for Sanger vs 2.5 
million for NGS), which will allow for better analysis of the microbial communities that 
are present. QPCR analysis will also be performed using primers G-Bifid-F and G-Bifid-
R to see if Bifidobacterium 16s rRNA relative abundance is influenced by yogurt 
consumption.
Future researchers who wish to analyze the effects on microbial communities 
should add more test subjects, specifically more controls, to truly understand how 
microbial communities are affected by yogurt consumption. Finally, to see if microbial 
communities return to their original state, a washout period after yogurt consumption 
should be included. 
Stress response, determined by cortisol enzyme immunoassay (EIA) from chapter 
III although statistically insignificant, decreased in healthy human test subject that 
consumed one probiotic pill per day. Control subjects on the other hand saw no drastic 
change in their stress response throughout the entire study. QPCR analysis showed an 
increase in Lactobacillus genes at Day 30 for individuals who consumed probiotics. 
Stopping the probiotic regimen at Day 30 resulted in a drastic decrease in Lactobacillus 
genes. Control subjects showed no drastic changes in Lactobacillus genes throughout the 
entire study.
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Future work for the chapter III study includes analyzing microbial communities 
by NGS using Bifidobacteria, Lactobacillus, archaeal, Fungal, and universal bacterial.
Morning saliva samples will be analyzed using a salivary cortisol EIA to determine the 
effects of probiotics on daily stress levels. QPCR analysis will be performed using 
primers G-Bifid-F and G-Bifid-R to see if Bifidobacterium 16s rRNA relative 
abundance is influenced by probiotic administration. Finally, perceived healthy and 
bowel health questionnaires will be analyzed to determine each individuals daily 
perceived stress as well as stress when performing EHC. The Bowel Health 
Questionnaire will be analyzed to describe any results that can be explained to 
various GI conditions (i.e. stomach flu).  
Recommendations for future researchers would be to increase the number of 
test subjects that participate. Increasing test subjects numbers may result in 
statistical significance in future work.   
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Appendix
I Detailed Protocols for Chapter 2
Powersoil DNA Isolation Kit Protocol
Mo Bio Laboratories, Inc.
Catalog No. 12888-50
Introduction
Powersoil DNA Isolation Kit is a method for isolating genomic DNA from environmental 
samples that contain high humic acid content including soil, compost, sediment, and 
manure.
Materials
- ȝOȝODQGȝOSLSHWWHVDQGWLSV
- PowerBead tubes (provided)
- Four 2 ml collection tube (provided)
- Spin filter
- Solutions C1, C2, C3, C4, C5, and C6
Method
1) Add 0.25 grams of fecal sample to PowerBead tubes and gentle vortex
2) $GGȝORIVROXWLRQ&DQGYRUWH[EULHIO\
a. Check solution C1. If solution C1 is precipitated, heDWDWÛ&XQWLO
dissolved
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3) Secure PowerBead tubes horizontally to horizontal vortex adapter and vortex at a 
maximum speed for 10 minutes
a. If using more than 12 preps, increase vortex time by 5-10 minutes
4) Centrifuge tubes at 10,000 x g for 30 seconds at room temperature
5) Transfer supernatant to clean 2 ml collection tube
a. Expect between 400-ȝO
6) $GGȝORIVROXWLRQ&DQGYRUWH[IRUVHFRQGVWKHQLQFXEDWHDWÛ&IRU
minutes
7) Centrifuge the tubes at room temperature for 1 minute at 10,000 x g
8) Avoiding the pHOOHWWUDQVIHUXSWREXWQRPRUHWKDQȝORIVXSHUQDWDQWWRD
clean  2 ml collection tube
9) $GGȝORIVROXWLRQ&YRUWH[EULHIO\DQGLQFXEDWHDWÛ&IRUPLQXWHV
10) Centrifuge the tubes at room temperature for 1 minute at 10,000 x g
11)$YRLGLQJWKHSHOOHWWUDQVIHUXSWRȝORIVXSHUQDWDQWLQWRDFOHDQPO
collection tube
12) Shake before use! $GGȝORIVROXWLRQ&WRWKHVXSHUQDWDQWDQGYRUWH[IRU
seconds
13)/RDGDSSUR[LPDWHO\ȝORIVXSHUQDWDQWRQWRDVSLQILOWHUDQGFHQWULIXJHat 
10,000 x g for 1 minute.
14)'LVFDUGWKHIORZWKURXJKDQGDGGDQDGGLWLRQDOȝORIVXSHUQDWDQWWRWKHVSLQ
filter and centrifuge at 10,000 x g for 1 minute
15) Load remaining supernatant onto spin filter and centrifuge at 10,000 x g for 1 
minute
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16)$GGȝOof solution C5 and centrifuge at room temperature for 30 seconds at 
10,000 x g
17) Discard flow through
18) Centrifuge again at room temperature for 10,000 x g at 1 min
19) Carefully place spin filter in a clean 2 ml collection tube 
a. Avoid splashing and C5 solution on spin filter
20)$GGȝORIVROXWLRQ&WRFHQWHURIZKLWHPHPEUDQHILOWHUDQGFHQWULIXJHDW
room temperature for 30 seconds at 10,000 x g
21) Discard spin filter. DNA is now ready for downstream application.
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QIAamp® DNA Stool Handbook
Qiagen 
Catalog No. 51504
Things to do before starting
- Ensure that Buffer AW1 and Buffer AW2 have been prepared according to the 
instructions on labels 
- Mix all buffers before use
- 3UHSDUHÛ&ZDWHUEDWK
Materials
- 4 microcentrifuge tubes
Procedure
1) Weigh 180-220 mg stool in a 2 ml microcentrifuge tube (not provided ) and place 
on ice
2) Add 1.6 ml Buffer ASL to each stool sample and vortex continuously for 1minute
3) Centrifuge sample at full speed for 1 minute to pellet stool particles
4) Pipet 1.4 ml of supernatant into a new 2 ml microcentrifuge (not provided)
5) Add inhibitEX Tablet to each sample and vortex for 1 minute or until tablet is 
completely dissolved
6) Incubate for 1 minute at room temperature
7) Centrifuge at full speed (16,000 x g) for 3 minutes 
8) Pipet all the supernatant into a new 1.5 ml microcentrifuge tube (not provided) 
and discard the pellet.
9) Centrifuge the sample at full speed for 3 minutes
10) 3LSHWȝOSURWHLQDVH.LQWRDQHZPOPLFURFHQWULIXJHWXEHQRWSURYLGHG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11) Add 600 ȝORIVXSHUQDWDnt from step 8 into the 2 ml microcentrifuge tube 
containing proteinase K
12) Add 600 ȝO%XIIHU$/DQGYRUWH[IRUVHFRQGVDQGLQFXEDWHDWÛ&IRU
minutes
13)$GGȝORIHWKDQRO-100%) to the lysate, and mix by vortexing
14) Label the lid of a new QIAamp spin column provided in a 2 ml collection
15)&DUHIXOO\DSSO\ȝOO\VWHIURPVWHSWR4,$DPSVSLQFROXPQZLWKRXW
moistening the rim
16) Close the cap and centrifuge at full speed for 1 minute.
17) Pace the QIAamp sin column in a new 2 ml collection tube, and discard the tube 
containing filtrate
18) Carefully open the QIAamp spin column, apply a second aliquot of 600 ȝOO\VDWH
and centrifuge at full speed for 1 minute.
19) Place the QIAamp spin column in a new 2 ml collection tube, and discard the tube 
containing filtrate
20) Repeat step s 18-19 for last lysate
21)&DUHIXOO\RSHQWKH4,$DPSVSLQFROXPQDQGDGGȝORI%XIIHU$:&ORVH
the cap and centrifuge at full speed for 3 minute
22) Discard the collection tube containing the filtrate
23) Place the QIAamp spin column in a new 2 ml collection tube (not provided) and 
discard the old collection tube with the filtrate.
24) Centrifuge at full speed for 1 minute
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25) Transfer the QIAamp spin column into a new, labeled 1.5 ml microcentrifuge tube 
(not provided)
26) 3LSHWȝORI%XIIHU$(GLUHFWO\RQto the QIAamp membrane .
27) Incubate at room temperature for 1 minute with the lid closed
28) Centrifuge at full speed for 1 minute to elute DNA
Samples are now ready for downstream application
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PCR and Terminal Restriction Fragment Length
Polymorphism (T-RFLP) Protocol
PCR protocol with primers 8F (FAM labeled) and 1492R
Materials
- Primers 8F (FAM) and 1492R
- Pipettes and Tips
- Genomic  DNA
- Molecular Grade Water
- Wizard® SV Gel and PCR Clean Up System (Promega)
- Restriction Enzyme Hae III
- 2ml Eppendorf Tubes
- 0.2 mL PCR tubes
Master Mix:
Molecular Grade Water: ȝO
Go Taq Green Master Mix: ȝO
8F-FAM : ȝO (10mM)
1492R: ȝO (10mM)
DNA ȝO
Thermocycler Settings:
- Û& for 3 min
- Û& for 30s
- Û& for 30s 30 cycles
- Û& for 1 min 30s
- Û& for 7 min
T-RFLP digestion with Hae III
1) $GGȝORI3&5SURGXFWWRȝORI+DH,,,ȝORIUHVWULFWLRQHQ]\PHWR
ȝORI'1$
2) ,QFXEDWHDWÛ&IRUKRXUV
3) Check for successful digestion by running a gel electrophoresis
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4) Perform PCR clean up using Wizard® SV Gel and PCR Clean Up System
Wizard® SV Gel and PCR Clean Up
Promega Labs
Catalog No. A9281
Procedure
1) Add and equal volume of membrane solution to PCR product
2) Insert SV minicolumn into provided collection tube
3) Transfer prepared PCR product to the minicolumn assembly and incubate at room 
temperature for 1 minute
4) Centrifuge at 16,000 x g for 1 minute
5) Discard the flow through and reinsert Minicolumn into collection tube
6) $GGȝO of Membrane Was Solution (ethanol added) and centrifuge at 16,000 
x g for 5 minutes
7) 5HSHDWVWHSZLWKȝORI0HPEUDQHZDVVROXWLRQDQGFHQWULIXJHDW[J
for 5 minutes
8) Empty collection tube and recentrifuge assembly for 1 minute with a new 
microcentrifuge tube. Keep lid of microcentrifuge tube open
9) Carefully transfer Minicolumn to a clean 1.5 mL microcentrifuge tube
10)$GGȝORIQXFOHDVH-free water and incubate at room temperature for 1 minute
11) Centrifuge at 16,000 x g for 1 minute
12) Discard minicolumn sample ready for downstream application
Send digested samples to the Ohio State University Plant Microbe and Genomics Facility 
(Columbus, OH USA) for fragment analysis using a 3730 DNA Analyzer (Applied 
Biosystems, Inc. Waltham, MA USA) using a LIZ1200 size standard and minimum peak 
height of 50 fluorescence units.
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Cloning
Precloning
LB Medium
20g of LB broth completed to 1 L of ddwater to a pH = 7 using 5N NaOH
Ampicillin
100 mg of Ampicillin in 1 mL of ddwater (100mg/mL). It can then be stored at -Û&
before filter sterilization.
LB-Ampicillin Agar (LB-AMP) (final conc. 0.1 mg/ml)
1) Prepare 1L of LB agar autoclaved
- LB agar autoclaved
o 20g LB broth
o 20g Triptic Soy Agar (TSA)
o Complete to 1L with ddwater and adjust pH=7 with 5N NaOH.
o Autoclave
2) Cool to Û&
3) $GGȝORIPJP/ILOWHU-sterilized ampicillin to 1L of autoclaved LB agar 
and mix by swirling
4) Pour LB-Ampicillin agar into petri dishes (~25 ml/ 100-mm plate)
3ODWHVFDQEHVWRUHGDWÛ&IRU-2 months.
Cloning
Materials:
- Strata Clone PCR Cloning Kit (Agilent Technologies)
o Cat. # 240205
- 2 ml microcentrifuge tubes (autoclaved)
Ligation- Day 1
1) Prepare the ligation reaction mixture by combining in order the  following 
components:
a. ȝO6WUDWD&ORQH&ORQLQJ%XIIHU
b.ȝORI3&5SURGXFW-50 ng) –or- ȝORI6WUDWD&ORQH&RQWURO,QVHUW
c. ȝO6WUDWD&ORQH9HFWRU0L[DPSNDQ
2) Mix gently by pipetting 
3) Incubate at room temperature for 5 minutes, then place the reaction on ice 
a. Reaction may be stored at -Û&IRUODWHUSURFHVVLQJ
Transformation-Day 1 or Day 2
- 6HWXSDZDWHUEDWKDWÛ&
- Check if pUC18 control is diluted 1:10, if not dilute using molecular grade 
water
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Immediately thaw one tube of StrataClone SoloPack competent cells (found in -Û&
freezer) on ice for each sample, for control insert and the pUC 18 control. Thawing takes 
1-2 minutes.
Procedure:
1)$GGȝORIFORQLQJUHDFWLRQRIHDFKVDPSOHWRDWXEHRIWKDZHGFRPSHWHQW
cells. Mix gently by pipetting 2 times
2)$GGȝORIGLOXWHGS8&WRDWXEHRIFRPSHWHQWFHOOV0L[JHQWO\
by pipetting 2 times
3)$GGȝORIFRQWUROLQVHUWWRDWXEHRIFRPSHWHQWFHOOV0L[JHQWO\E\
pipetting 2 times
4)Incubate transformation mixture on ice for 20 minutes. 
a. During this time pre-ZDUP/%PHGLXPLQÛ&ZDWHUEDWK
5)+HDWVKRFNWKHWUDQVIRUPDWLRQPL[WXUHDWÛ&IRU5s
6)Incubate transformation mixture on ice for 2 minutes
7)$GGȝORISUH-warmed LB medium to transformation reaction mixture
8)$OORZWUDQVIRUPDWLRQWRUHDFWLRQWRUHVWIRUKRXUDQGPLQXWHVDWÛ&
in a shaker at 360 rpms. 
a. During this time , spread 40 ȝORI;-gal onto each LB-
AMP plate
9)3ODWHRXWWZRȝORI&RQWURO,QVHUWDQGWZRȝORIS8&RQWR;-
gal LB-AMP plates
10) 3ODWHRXWȝORQWRWZRSODWHV
11) 3ODWHȝORQWRWZRSODWHV
a. :KHQSLSHWWLQJȝORIWUDQVIRUPDWLRQPL[WXUHDGGȝO of LB 
medium to transformation mix, gently vortex.
12) 3ODWHȝORQWRWZRSODWHV
13) ,QFXEDWHSODWHVDWÛ&RYHUQLJKW
Analysis-Day 3
Materials:
- UV’d 96 well plate for 1 hour or use autoclaved 96 well plates. 
- Autoclaved tray for multichannel pipettor
- Autoclaved toothpicks
Prepare LB AMP 10% glycerol:
For 1 well-plate - 40 ml LB Amp 10% glycerol 
1),QDVWHULOH)DOFRQWXEHFRPELQHPORI/%EURWKDQGȝORIILOWHU
sterilized ampicillin, vortex and transfer 36 ml of this solution to another 
36 ml sterile Falcon tube.
2)Add  4 ml of glycerol to 36 ml of LB AMP broth and  vortex  (this makes 
LB AMP 10% glycerol)
3))LOOZHOOSODWHZLWKȝORI/%$03JO\FHURO
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Inoculating LB AMP 10% glycerol with colonies (not from Control Insert or pUC 18
control) formed from overnight incubation performed on Day 3
1) Pick white colonies with toothpicks and inoculate each well (skip wells A1 
and B1).
a. Use new toothpick for each colony
b. Leave toothpicks in the row just competed as a placeholder, complete 
the next row and then remove toothpicks from the previously 
completed column. Repeat until all wells completed
2) Place protective film over the plate
3) ,QFXEDWHRYHUQLJKWDWÛ&ZKLOHVKDNLQJDWUSPV
The control insert should have >100 colonies per plate. 97% or more should be white 
colonies. The pUC18 should have > 50 blue colonies.
Confirmation – Day 4
1) Remove well plates from incubator
2) 8VLQJDPXOWLFKDQQHOSLSHWWRUWUDQVIHUȝORQWRDQHZ89VWHULOL]HGRU
autoclaved 96 well plate.
3) Cover 96 well plate with film and store at -Û&
Use subsample for PCR confirmation of sample insert
a.8VHȝORIVWRFNFHOOVRIVDPSOHIRUDȝO3&5
b. Use primers 8F and 1492R for PCR
c. Run gel to verify size fragments
4) 8VHILOPWRFRYHUUHPDLQLQJȝODQGVWRUHDWÛ&
5) $IWHU3&5FRQILUPDWLRQWDNHȝODQGSODFHLWLQDDXWRFODYHZHOOSODWHFRYHU
with film and store at -Û&
a. Samples are now ready to be shipped on dry ice for sequencing
6) &RYHUVDPSOHVZLWKILOPDQGVWRUHUHPDLQLQJVDPSOHVȝODW-Û&
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Quantitative PCR 
 
Keep everything on ICE 
SYBR Green is light sensitive, keep cold and dark as much as possible. 
UV everything beforehand.  Sterility is key. 
 
1.  Serial Dilutions of Standards 
a. Serially dilute standard DNA and keep on ice. 
b. 7 dilutions and a blank of only water will be necessary. 
c. Dilutions will vary, see example below. 
2. Prepare master mix (without SYBR Green) 
a. Add nuclease free water first 
b. Add both forward and reverse primers 
3. Add DNA to wells of 96 well plate 
4. Add SYBR Green to master mix 
5. Add master mix to wells of 96 well plate 
6. In Dr. Cooper’s lab: 
a. Turn on thermocycler (bottom switch) 
b. Turn on camera (top switch)  [Note: camera takes 10min to warm up] 
c. Centrifuge 96 well plate up to 600 rpm then stop 
7. On the computer: 
a. Turn on computer if necessary and open program (Bio-Rad) 
b. Workshop, Add plate, create new 
c. Flourophore is SYBR Green 1 
d. Enter experiment name 
e. Enter standard information (concentration), select units and dilution 
factor. 
 
 
 
It is a good idea to normalize your unknowns to the same concentration as well and 
depending on your goals (relative quantification versus absolute quantification) it 
may be necessary. 
 
Standard Serial Dilution example: 
 
For a 1:10 Dilution: 
7 tubes, each starts with 18 uL of water. 
Add 2 uL of Standard DNA to the first tube (Tube 1) and mix by pipetting. 
Take 2 uL from Tube 1 and add to Tube 2 then mix by pipetting. 
Take 2 uL from Tube 2 and add to Tube 3 then mix by pipetting. 
Continue until serial dilution is complete. 
 
x Standards must be quantified before use and should be normalized to the 
same concentration. 
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x Ideally, a tenfold dilution should be used for the serial dilution of standards. 
x Standards should be prepared/serially diluted per use to avoid freeze/thaw 
effects.  Standards can be stored and used one or twice. 
 
 
Plate set up example 
 
STD 1 STD 1 STD 1          
STD 2 STD 2 STD 2          
STD 3 STD 3 STD 3          
STD 4 STD 4 STD 4          
STD 5 STD 5 STD 5          
STD 6 STD 6 STD 6          
STD 7 STD 7 STD 7          
BLANK BLANK BLANK          
 
x STD are your standards of known concentrations run in triplicate. 1-7 
represent the serial dilutions (i.e. STD 1 is diluted 10-1, STD is diluted to 10-2, 
and so on). 
x BLANK is your negative control.  This receives water instead of DNA, but is 
otherwise treated as normal. 
x Empty cells are for your samples.  Samples should be run in triplicate. 
 
qPCR Reaction set up: 
 
  1 Reaction (25 uL) 
SYBR  12.5 uL 
Primer 1 0.5 uL 
Primer 2 0.5 uL 
DNA  2.5 uL 
Water  9.0 uL 
Total:  25.0 uL 
 
x Multiply all volumes by number of samples (Standards + blanks + unknowns 
+ extra[to account for pipetting error]) to make a master mix. 
x When making master mix, DO NOT add DNA.  DNA will be added to the wells 
separately. 
x Note in protocol that SYBR green gets added last to the master mix, after DNA 
has already been added to the wells. 
x When adding master mix to wells, add total volume per reaction minus the 
DNA (i.e. for 25 uL reaction using 2.5 uL DNA per reaction, add 22.5 uL 
master mix to each well) 
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Youngstown State University Institutional Review Board
Informed Consent Form for Research Involving Human Subjects 
Protocol Title: Effects of Yogurt Consumption on Gut Microbial Communities
Principal Investigator: Dr. Carl Johnston
YSU: Biology Department
1. Introduction
You are being asked to take part voluntarily in the research project described below. 
Please take your time making a decision and feel free to discuss it with your friends and 
family. Before agreeing to take part in this research study, it is important that you read 
the consent form that describes the study. Please ask the study researcher or the study 
staff to explain any words or information that you do not clearly understand.
2. Why is this study being done?
You have been asked to take part in a research study to determine the effect of probiotic 
pills on the microbial community within the human intestinal tract. 
You are one of six subjects participating in this study at YSU.
You are being asked to be in the study because you are an individual in good health, you 
have no known adverse reactions to probiotics, able to collect your own stool samples, 
and are willing and capable of following a probiotic/antibiotic free diet for one week 
followed by a daily consumption of one probiotic pill per day for 30 consecutive days,.
If you decide to enroll in this study, your involvement will last 60 days.
3. What is involved in the study?
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If you agree to take part in this study, the research team will:
Provide you with three 150 g (about the size of one yogurt container commonly sold at 
super markets) servings of yogurt for you to eat each day for 3 weeks.
Provide you with sterile 30 ml wide mouth containers (to avoid leaks) for which you are 
to collect your stool samples when sample is collected participants will place lid and 
close the container to avoid contamination. The container will be placed in a double 
Ziploc bag and kept in a cooler on ice before and during transportation to the laboratory. 
Hands should be cleaned using soap and water or hand sanitizer. Stray material should 
be cleaned using sanitary wipes and disinfectant. Any leakage must be cleaned using 
disinfectant or soap and water. You will provide stool samples to the research team at the 
start of the study and then once every 15 days for a total of 5 stool samples.  Each 
container with a stool sample will be labeled by the investigator with the date of 
collection and will be marked with a letter of the alphabet (not with your name) upon 
receiving.
- Fecal samples must not be in contact with any other surfaces (including hands, 
toilet paper, wipes, etc) other than the collection sterile cap. If by mistake stools 
fall into the toilet bowl or feces touch any other surface, those fecal samples 
cannot be longer used. The participant will have to collect another stool sample in 
their next bowel movement.
Each human subject also agrees to consume no probiotics (i.e. yogurt, probiotic pills, 
kefir etc.) for two weeks, followed by consuming one probiotic pill per day for 30 
consecutive days
- There is not a typical amount to ingest according to the US dietary guidelines, 
however, based on other sources of information (e.g. yogurt demand) the average 
weekly amount of yogurt is 100 g based on national averages on the whole 
population. 
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- The amount in the experiment is much more than “average” ingested. Small 
single portion of yogurt range from 113 g to 150 g and are commonly sold in 
detachable containers.
4. What are the risks and discomforts of the study?
There are no known risks associated with probiotic pill consumption. Nor is there risk 
associated with increased risk of developing lactose intolerance. Only individuals with a 
prior history of regular consumption of probiotics are asked to be in this study. Only
individuals trained in microbiology and are able to properly collect their own samples 
will be asked to participate in this study.
5. What will happen if I am injured in this study?
The Youngstown State University and its affiliates do not offer to pay for or cover the 
cost of medical treatment for research related illness or injury. No funds have been set 
aside to pay or reimburse you in the event of such injury or illness. You will not give up 
any of your legal rights by signing this consent form. You should report any such injury 
to Carl Johnston (phone 330 941 7002) and to the YSU Institutional Review Board (IRB) 
at (330-941-2377). If a participant develops i.e. diarrhea he/she should contact his/her 
physician. Participants can also call Dr. Johnston at (330) 941-7002.
6. Are there benefits to taking part in this study?
There will be no direct benefits to you for taking part in this study. This research may 
determine what microbes are found in your intestinal tract and if probiotic pills have any 
effect on the microbial community within your intestinal tract. 
7. What other options are there?
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You have the option not to take part in this study. There will be no penalties involved if 
you choose not to take part in this study.
8. Who is paying for this study?
Internal Funding:
Funding to initiate this study is provided by YSU Department of Biological 
Sciences. Funding has been requested from the YSU College of Graduate Studies 
and Research. 
External funding:  N/A
9. What are my costs?
There are no direct costs. You will be responsible for travel to and from the research site 
and any other incidental expenses.
10. Will I be paid to participate in this study?
You will not be paid for taking part in this research study
11. What if I want to withdraw, or if I am asked to withdraw from this study?
Taking part in this study is voluntary. You have the right to choose not to take part in this 
study. If you do not take part in the study, there will be no penalty.
If you choose to take part, you have the right to stop at any time. However, we encourage 
you to talk to a member of the research group so that they know why you are leaving the 
study. If there are any new findings during the study that may affect whether you want to 
continue to take part, you will be told about them.
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The researcher may decide to stop your participation without your permission, if he thinks 
your participation in the study may cause you harm. An example of harm would be 
appearance of symptoms of lactose intolerance.  
12. Who do I call if I have questions or problems?
You may ask any questions you have now. If you have questions later, you may call
Dr. Carl Johnston (phone: 330-941-7151, email cgjohnston@ysu.edu).
If you have questions or concerns about your participation as a research subject, please 
contact Dr. Ed Orona, Director of Grants and Sponsored Programs at YSU.
13. What about confidentiality?
1. Your part in this study is confidential. None of the information will identify you by name. 
All records from samples you provide will be labeled as A, B, C, D, E, or F throughout the 
experiment. These labels will refer to all data collected from subject A – F. 
2. Every effort will be made to keep your information confidential. Your personal 
information may be disclosed if required by law. Organizations that may inspect and/or copy 
your research records for quality assurance and data analysis include, but are not necessarily 
limited to:
The sponsor or an agent for the sponsor
Department of Health and Human Services
YSU Institutional Review Board
Because of the need to release information to these parties, absolute confidentiality cannot be 
guaranteed. The results of this research study may be presented at meetings or in 
publications; however, your identity will not be disclosed in those presentations. 
All records will be maintained as follows:   
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Confidentiality documents will be kept locked within Dr. Johnston’s office (room 4006 WB) 
and will be kept separate from all other data collected from this study.
No other documents will mention you by name and you will only have a letter representing 
data from you. Information associated with you as a subject (designated only by a letter of 
the alphabet) will be stored in electronic and paper formats and will be released to the public 
as scientific papers or presentations (with no reference to identity).
3. Participants in this study will be kept confidential with the exception as described above.  
14. Mandatory reporting:  Not Applicable
15. Authorization Statement
I have read each page of this paper about the study. I know that being in this study is 
voluntary and I choose to be in this study. I know I can stop being in this study without 
penalty. I will get a copy of this consent form now and can get information on results of the 
study later if I wish.
Participant Name: 
Date:
Consent form explained/witnessed by: 
Signature:
Printed name:
Date: Time:
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II Detailed Protocols for Chapter 3
Salivary Cortisol ELISA
Reagent Preparation:
1) Bring all reagents to room temperature 
a. 1.5 hrs need for 24 mL of assay diluent used in step 5
2) Bring microtitre plate to room temperature before use
a. Keep the pouch closed until warmed to room temperature
3) Prepare a 1x wash buffer by diluting 10x wash buffer with deionized water
a. Dilute only enough for current days use
i. Discard any leftover reagent
4) Prepare a tube with 24 mL of assay diluent for conjugate solution (scale down if 
necessary). 
a. Caluclate amount of conjugate needed to make 1:1600 dilution (for a 96-well 
plate add 15Ɋto 24 ml assay diluent)
DO NOT ADD CONJUGATE TO ASSAY DILUENT UNTIL STEP 3
Procedure:
1) 3LSHWWHȝORIVWDQGDUGVFRQWUROVDQGXQNQRZQVLQWRDSSURSULDWHZHOOVRI-
well plate
2) 3LSHWWHȝORIDVVD\GLOXHQWLQWR]HURDQGQRQ-specific binding (NSB) wells 
3) 0DNHDGLOXWLRQRIFRQMXJDWHPL[DQGLPPHGLDWHO\SLSHWWHȝOLQWR
each well
4) Mix plate by on rotator for 5 minutes at 500 rpm or mix by swirling on table
5) Incubate at room temperature for 55 minutes
6) Aspirate off solution
7) :DVKVDPSOHVE\SLSHWWLQJȝORI[ZDVKEXIIHULQWRHDFKZHOO
8) Aspirate of solution
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9) Repeat steps 7-8 three more times
10)$GGȝORI70%VROXWLRQWRHDFKZLOOXVLQJDPXOWLFKDQQHOSLSHWWH
a. May see color change immediately
11) Mix on a plate rotator for 5 minutes at 500 rpm or mix by swirling on table
12) Incubate the plate in the dark at room temperature for 25 minutes or until good 
blue color developes.
a. Check every 5 minutes
13)$GGȝORIVWRSsolution to each well with multichannel pipette
14) Mix on plate rotator for 3 minutes at 500 rpm or mix by swirling on table
15) Read plate at 450 nm within 10 minutes of adding stop solutions
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Modified DNA Stool Mini Kit 
Reference:  
Yu, Z. and M. Morrison. 2004. Improved extraction of PCR-quality community DNA 
from digesta and fecal samples. Biotechniques 36:808-812.
Reagents (not included in kit):
Tris-HCl (500 mM, pH 8.0): Place 30.28g of Tris in a 500 mL volumetric flask; 
add ~300 mL milliQ water. Then bring to pH 8.0 by adding concentrated (1M or higher) 
HCl, then add milliQ water to volume.
EDTA (500 mM, pH 8.0): Place 93.05g of EDTA Disodium Salt Dihydrate in a 
500 mL volumetric flask; add ~300 mL milliQ water – heating helps EDTA dissolve; 
adjust pH close to 8.0 (EDTA only completely dissolves at ~pH 8.0 – when all is 
dissolved, adjust pH to 8.0, then bring to volume). Autoclave for 15 minutes (if 
immediately making a solution with this stock, you can use the fresh EDTA solution)  
Lysis solution: Place 7.3 g of NaCl and 10 g SDS in an autoclavable bottle; add 
25 mL of 500mM Tris-HCl; add 25 mL of 500mM EDTA; add 200mL milliQ water. Stir 
on a hotplate/stirrer (medium temperature) to dissolve the SDS (this takes a while) – do 
NOT shake agressively, this solution foams excessively. Take out the stir bar, then 
autoclave.
NOTE: This solution separates easily – after autoclaving, a STERILE stir bar can be 
added back. Stir on a medium temperature hotplate before use (solution should be clear)
10M NH4-Acetate: place 38.54 g Ammonium acetate in a 50 mL volumetric 
flask; bring up to volume. Mild heating will ease dissolving.
TE buffer: pipet 10mL Tris-HCl (500 mM) and 1mL of 500mM EDTA into a 
500mL volumetric flask. Bring to volume, autoclave for 15 minutes.
70% ethanol: bring 70mL of 100% ethanol to 100 mL volume
100% ethanol
Isopropanol
DNase-free RNase: get at the life sciences store-room (Roche catalog 
#11119915001) in 1 mL tube – good for ~25 extractions. If you know you need large 
quantities (many extractions) you may want to order directly from Roche – the store 
room only has a few vials in stock.
Procedure:
Day 1:
Cell Lysis:
Suggestion for fecal samples: do a 105 dry matter on the sample you actually extract. 
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Turn on the water baths to 37 & 70C, and let the centrifuge cool to 4C
To ensure all fluid is incubated properly, you need to spin your tubes in the micro-
centrifuge for 2-3 seconds – this is referred to as “quick-spin”
- Weigh up 0.4 g of sterile zirconia/glass beads in 2-mL screw-cap tubes using 
the porcelain scoop
o 0.4g Disruption Beads (RPI 9830)
- Transfer 0.25 g (or 400ul for in vitro samples) of sample into a fresh 2-mL 
screw-cap tube (acceptable weight range: 0.20 – 0.32 g) – try to keep the rim 
clean and to not have the sample stick to side of the tube.
- Add 1 mL of lysis solution to the tube and vortex at full speed until beads and 
sample are reasonably mixed (make sure no sample is sticking to the wall of 
the tube)
- Homogenize for 3 min at maximum speed with a vortex (tube adapter)
- Incubate at 70oC for 15 min with gentle shaking (inverting) by hand every 5
min
- Centrifuge at 4oC for 5 min at 16,000 X g
- Pipet the supernatant into a fresh 2-mL Eppendorf tube 
- Add 300 PL of fresh lysis buffer to the screw-cap tube
- Vortex until mixed – make SURE to break up the pellet at the bottom of the 
tube
- Homogenize for 3 min at maximum speed with a vortex (tube adapter)
- Incubate at 70oC for 15 min with gentle shaking (inverting) by hand every 5
min
- Centrifuge at 4oC for 5 min at 16,000 X g.
- Combine the supernatant with the supernatant collected previously
Precipitation of nucleic acids
- Add 260 PL of 10 M ammonium acetate to each tube, vortex to mix.
- Incubate on ice for 5 min
- Centrifuge at 4oC for 10 min at 16,000 X g
- Transfer (split) supernatant into two 1.5-mL Eppendorf tubes (use fixed 
volume, 600 PL will get you most, if not all supernatant)
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- Add an equal volume of isopropanol to each eppendorf and mix well
- Incubate on ice for 30 min
- Centrifuge at 4oC for 15 min at 16,000 X g
- Carefully pipet off the supernatant, make sure to leave pellet intact!
- Wash the nucleic acids pellet by adding 0.5 mL with 70% ethanol, centrifuge 
at 4oC for 1 minute at 16,000 X g (to make sure the pellet is intact), then 
carefully pipet off ethanol – do not damage the pellet!
NOTE: after this step, set the centrifuge to warm up to room temp for the next 
centrifugation steps
- Dry the pellet in a BSC for 30 mins
- Dissolve the nucleic acid pellet in 100 PL of TE (Tris-EDTA) buffer, this 
takes some effort – pellet is re-hydrated overnight at 4C.
Day 2:
- Pool the two aliquots of dissolved pellet into one tube
Removal of RNA
- Add 40 PL of DNase-free RNase (final [0.1 Pg/PL]). Vortex and quick-spin.
- Incubate at 37oC for 15 min
Part II:
Removal of protein and purification (partial Qiagen Stool mini kit – centrifugation at 
ROOM TEMPERATURE)
- Add 15 PL of proteinase K, vortex and quick-spin
- Add 200 PL of Buffer AL, vortex and quick-spin
- Incubate at 70oC for 10 min
- Add 200 PL of ethanol, vortex and quick-spin, and pipet all liquid to a QIAmp
column (don’t wet the rim) and centrifuge at 16,000 X g for 1 min at room 
temp
- Insert columns into a new 2 mL collection tube
- Add 500 PL of Buffer AW1 and centrifuge at 16,000 X g for 1 min, insert 
columns into new 2 mL collection tube
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- Add 500 PL of Buffer AW2 and centrifuge at 16,000 X g for 1 min, insert 
columns into new 2 mL collection tube
- Dry the column by centrifugation at RT for 1 min (16,000 X g), insert 
columns into an appropriately labeled 1.5 mL eppendorf tube
- Add 200 PL of Buffer AE and incubate at RT for 4 min
- Centrifuge at RT for 1 min to elute DNA and read a 2 PL sample on the Nano-
drop spec
- Freeze samples at -20oC for storage or until further use
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Perceived Stress Questionnaire
For each sentence, mark the number that describes how often it applies to you in 
general, since the last sampling period.  Work quickly, without bothering to check 
your answers. 
 
Almost Never = 1 
Sometimes = 2 
Often = 3 
Usually = 4 
 
1. You feel rested 
2. You feel that too many demands are being made on you 
3. You are irritable or grouchy 
4. You have too many things to do 
5. You feel lonely or isolated 
6. You find yourself in situations of conflict 
7. You feel like you’re doing things you really like 
8. You feel tired 
9. You fear you may not manage to attain your goals 
10. You feel calm 
11. You have too many decisions too make 
12. You feel frustrated 
13. You are full of energy 
14. You feel tense 
15. Your problems seem to be piling up 
16. You feel like you’re in a hurry 
17. You feel safe and protected 
18. You have many worries 
19. You are under pressure from other people 
20. You feel discouraged 
21. You enjoy yourself 
22. You are afraid for the future 
23. You feel you’re doing things because you have to not because you want to 
24. You feel criticized or judged 
25. You are lighthearted 
26. You feel mentally exhausted 
27. You have trouble relaxing 
28. You feel loaded down with responsibility 
29. You have enough time for yourself 
30. You feel under pressure from deadlines 
 
31. During the stress induction, how stressed did you feel? Rank on a level of 1-
10 with one being less stressed and ten being highly stressed. 
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Bowel Health Questionnaire (BHQ) 
 
For each sentence, mark the number that describes how often it applies to you in 
general, since the last sampling period.  Work quickly, without bothering to check 
your answers. 
 
Almost Never = 1 
Sometimes = 2 
Often = 3 
Usually = 4 
 
1. During the last 2 weeks, how often have you had discomfort or pain in your 
abdomen? 
2. During the last 2 weeks, how often have you had discomfort or pain in your 
abdomen after eating? 
3. How often in the past 2 weeks have you suffered from feeling an urgency 
(feeling that you must immediately rush to the toilet to pass a stool)? 
4. Have you lost any sleep do to discomfort to abdominal pain or discomfort in 
the past 2 weeks? 
5. In the past two weeks, your stool was very hard? 
6. In the last 2 weeks, how often did you have loose, mushy, or watery stools?  
7. In the past two weeks, how often have you had flatulence? 
  
For the following questions please write down an estimated amount for each. 
 
 
1. How often have you had bowel movements in the past 2 weeks? 
 
 
2. In the past 2 weeks, how often have you been constipated? 
 
 
3. In the past 2 weeks, how often have you had diarrhea? 
 
 
4. How many times in the past 2 weeks have you taken laxatives or stool 
softeners? 
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Youngstown State University Institutional Review Board
Informed Consent Form for Research Involving Human Subjects 
Protocol Title: Effects of Probiotics on Human Gut Microbial Community 
Composition and Stress
Principal Investigator: Dr. Carl Johnston
YSU: Biology Department     
1. Introduction
You are being asked to volunteer in the research project described below. Please take 
your time making a decision. Feel free to discuss it with your friends and family. Read 
the consent form describing the study before you agree to take part. Ask the researcher to 
explain anything that you do not understand.
2. Why is this study being done?
You have been asked to partake in this study to determine the effect probiotic pills have
on stress and the microbial community of the human gut. 
You are one of 20 subjects in this study.
You are being asked to be in this study because you are:
- Of good health
- Have no known adverse reactions to probiotics (Such as gas or bloating)
- Able to collect your own stool samples
- Willing to take one probiotic pill per day for 30 consecutive days.
If you decide to join in this study, your commitment will last 60 days. 
Which includes:
- 30 days of probiotic pill intake 
- 30 days normal diet
3. What is involved in the study?
- If you agree to take part in this study, you will be provided with one pack of pr
obiotic pills (30 pills). You will be required consume the “average” amount of 
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one pill per day for 30 consecutive days
While in this study, you should avoid the use of antibiotics.  Antibiotics may interfere with 
results.  If a physician prescribes antibiotics, you should take them but report this to the 
investigator.
Saliva Collection
We will provide you with a sterile Salivettes® to collect a saliva sample.
- Saliva samples will be collected once before and 20 minutes after elevated high 
rope course.
Procedure
- Remove sterile cotton from plastic tube (salivette)
- Place it under your tongue and keep it in your mouth until saturated.
- Once saturated, place the cotton back into the plastic tube, cap tightly and label.
Samples can be kept at room temperature but must be turned into a lab tech on sampling 
day. Sampling will be at baseline and every 15 days after that for a total of 5 samples 
over 60 days.
Please refrain from:
- Eating food or drinking beverages during sample collection. 
- Drinking coffee 1 hour before collection. 
If you think there is contamination of the salivette® discard it and use a new one. 
Fecal Collection
You will provide a fecal sample at the start of this study and then once every 15 days for 
a total of 5 stool samples.
Provided materials:
T 30 ml sterile wide mouth container
T Gloves
T Double Ziploc bag
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Collection Procedure
T Collect fecal samples in 30 ml wide mouth container.
T Place lid on container to avoid contamination
T Label and date container
T Place container in Ziploc bag
T Keep sample on ice
T Give sample to researcher
Wash hands after sample collection with soap and water or hand sanitizer.
Stray material or leakage should be cleaned using sanitary wipes and disinfectant. 
Samples can no longer be used if:
- They touch any other surfaces (including hands, wipes, etc.) other than the collect
ion tubes. 
- By mistake stool falls into the toilet bowl. Collect another stool sample during yo
ur next bowel movement.
Fecal and saliva material that touch anywhere other than the interior of the collection tube 
must be cleaned immediately using sanitary wipes or disinfectant.  Sample material could 
be harmful for other individuals if they come into contact with it.
Dietary/Exercise Log
You are required to keep a daily dietary/exercise log to provide general information of 
your diet and exercise. 
A journal will be provided for you to record:
- daily food and water consumption. 
- daily exercise and its intensity 
Make note in the journal if you feel ill, used any antibiotics, or have consumed any other 
forms of probiotics other than those provided. 
Perceived Stress Questionnaire
Every sampling day a survey will be provided to you. 
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The survey will consist of 42 items:
- 30 questions about daily life stressors
- one question on how you felt during elevated high ropes course
- 10 questions on digestive health
4. What are the risks and discomforts of the study?
To take part in this study you must have:
- A prior history of probiotic use 
- No history of adverse effects (gas and bloating) from probiotics
Talk to a researcher about dropping the study if you experience any adverse effects. 
The risks associated with sample collection include:
- Getting saliva or fecal material on your hands.  
o Some infectious diseases can be transmitted through fecal material and 
bodily fluids. 
o Since you will be collecting your own samples, there should be no risk to 
you as a participant.  
o Wear gloves and wash your hands after sample collection to avoid 
contamination. 
If you are aware that you have any diseases that may be transmitted in this manner please 
inform the researcher.
Risk associated with elevated high ropes course:
This study involves inducing stress through elevated high ropes course. 
- Individuals with balance issues or a heart problem should not participate in this 
study.  
- Minimal psychological risk associated with this task.  
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o If you have an extreme fear of heights, this task may be very 
psychologically stressful 
- If you feel you cannot complete the task:
o stop at that point return to base platform 
o or you may resign from the study
Trained staff will be present at all times to ensure safety, supervise, and to demonstrate. If 
by an unlikely chance that an adverse event were to occur, there is an emergency medical 
kit located at the facility and a pulley system is present to lower participants to the ground 
floor.
5. What will happen if I am injured in this study?
Youngstown State University and its affiliates offer no compensation for research related 
illness or injury. You will not give up any of your legal rights by signing this consent 
form. 
If you develop any illness or injury (i.e. diarrhea), you should contact one of the 
following:
- Carl Johnston (phone 330-941-7002) 
- YSU Institutional Review Board (IRB) (phone 330-941-2377)
- Your physician. 
6. Are there benefits to taking part in this study?
- There will be no direct benefits to you for taking part in this study.
- This research may determine what microbes are found in your intestinal tract 
7. What other options are there?
- You have the option not to take part in this study.
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- There will be no penalties involved if you choose not to take part in this study.
8. Who is paying for this study?
Internal Funding:
YSU Department of Biological Sciences provides funding for this study. Funding 
has been requested from the YSU College of Graduate Studies and Research. 
External funding:  N/A
9. What are my costs?
Travel to and from Youngstown State University, and any other incidental expenses, such 
as disinfectant or gloves.
10. Will I be paid to participate in this study?
You will not be paid for taking part in this study.
11. What if I want to withdraw, or if I am asked to withdraw from this study?
- Taking part in this study is voluntary. 
- You have the right to choose not to take part in this study.
- There will be no penalty if you do not take part in the study.
- You have the right to stop at any time, but we recommend talking with a 
researcher first. 
- You will be told about any new findings that may affect your decision to take part 
in this study.
The researcher may decide to stop your participation without your permission:
- If he thinks your participation in the study may because you harm. 
o An example of harm would be appearance of symptoms of lactose 
intolerance.  
 
 
89 
 
12. Who do I call if I have questions or problems?
If you have any questions during the study you may contact Dr. Carl Johnston 
- phone: 330-941-7151
- Email: cgjohnston@ysu.edu.
If you have questions or concerns about your participation as a research subject, contact Dr. 
Ed Orona, Director of Grants and Sponsored Programs at YSU.
13. What about confidentiality?
1. Your part in this study is confidential. 
a. No information will identify you by name.
b. The Principal Investigator (Dr. Johnston) will assign a non-identifying label  to 
you.
c. Only Dr. Johnston will have access to the log that links you to your label.
2. This consent form and any confidentiality documents (as mentioned above) will be 
locked in Dr. Johnston’s office. Every effort will be made to keep your information 
confidential. 
3. Your personal information may be disclosed if required by law. Organizations that may 
inspect and/or copy your research records for quality assurance and data analysis include 
but are not necessarily limited to:
- The sponsor or an agent for the sponsor
- Department of Health and Human Services
- YSU Institutional Review Board
Absolute confidentiality cannot be guaranteed because of the need to release information to 
these parties. 
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The results of this research study may be presented at meetings or in publications. Your 
identity will not be disclosed in those presentations. 
Non-identifying information associated with you as a subject will be stored in electronic and 
paper formats.  This information will be released to the public as scientific papers or 
presentations.
4. Your name will be kept confidential with the exception as described above.  
14. Mandatory reporting:  Not Applicable
15. Authorization Statement
- I have read each page of this paper about the study.
- I know that being in this study is voluntary and I choose to be in this study.
- I know I can stop being in this study without penalty. 
- I will get a copy of this consent form now and can get information on results of 
the study later if I wish.
Participant Name: 
Date:
Consent form explained/witnessed by: 
Signature:
Printed name:
Date: Time:

